Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.55 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650788 | 1.00 | USP30 (0.55) | USP30PRKAA2HDAC4HDAC6GPR119 | |
| SCHEMBL648780 | 1.00 | USP30 (0.55) | USP30PRKAA2HDAC4HDAC6GPR119 | |
| SCHEMBL3668147 | 0.89 | PRKAA2 (0.49) | USP30PRKAA2EPHX2LPLLIPG | |
| SCHEMBL12265115 | 0.85 | USP30 (0.54) | USP30PRKAA2HDAC4HDAC6GPR119 | |
| SCHEMBL12199280 | 0.85 | EPHX2 (0.45) | PRKAA2EPHX2LPLLIPGSCN9A | |
| SCHEMBL1034128 | 0.84 | GPR119 (0.49) | USP30PRKAA2HDAC4GPR119MEN1 | |
| SCHEMBL650732 | 0.83 | EPHX2 (0.48) | USP30PRKAA2HDAC4GPR119EPHX2 | |
| SCHEMBL25242688 | 0.82 | USP30 (0.58) | USP30PRKAA2GPR119EPHX2 | |
| SCHEMBL31362184 | 0.82 | USP30 (0.58) | USP30PRKAA2GPR119EPHX2 | |
| SCHEMBL649869 | 0.81 | HDAC4 (0.46) | USP30HDAC4HDAC6GPR119PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | claimed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9174964-B2 | AMPK-activating piperidinyloxy-substituted 2,3-dihydro-1H-indene-1-amine compounds and pharmaceutical compositions including the same | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140323460-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | MIDCAP FINANCIAL TRUST | 2014-10-30 | — | — | US | disclosed |
| US-8796254-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140051673-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8569340-B2 | AMPK-activating piperidinyloxypyiridine carboxamide and sulfonamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8119809-B2 | AMPK-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | USP30 2627/4885PRKAA2 413/4885HDAC4 335/4885 |
| US-20140323460-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | USP30 2627/4885PRKAA2 413/4885HDAC4 335/4885 |
| US-20140051673-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | USP30 2371/4885PRKAA2 2/4885HDAC4 957/4885 |
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | USP30 2371/4885PRKAA2 2/4885HDAC4 957/4885 |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | CPT2, SHMT2, CS | USP30 3988/4885PRKAA2 356/4885HDAC4 1466/4885 |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | USP30 2665/4885PRKAA2 3/4885HDAC4 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.